However, in contrast to a large case-only analysis of 2014 women with IBC [27], we could not demonstrate any prognostic difference between patients with HER2-positive disease as compared to patients with HER2-negative disease. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.